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Seoul, Gwangju, Daejeon, Bucheon, Wonju, Suwon, Changwon, and Daegu, Republic of KoreaObjectives The authors sought to investigate whether the impact of treatment strategies on clinical
outcomes differed between patients with left main (LM) bifurcation lesions and those with non-LM
bifurcation lesions.
Background Few studies have considered anatomic location when comparing 1- and 2-stent
strategies for bifurcation lesions.
Methods We compared the prognostic impact of treatment strategies on clinical outcomes in 2,044
patients with non-LM bifurcation lesions and 853 with LM bifurcation lesions. The primary outcome
was target lesion failure (TLF) deﬁned as a composite of cardiac death, myocardial infarction (MI), and
target lesion revascularization.
Results The 2-stent strategy was used more frequently in the LM bifurcation group than in the non-
LM bifurcation group (40.3% vs. 20.8%, p < 0.01). During a median follow-up of 36 months, the 2-stent
strategy was not associated with a higher incidence of cardiac death (hazard ratio [HR]: 1.24; 95%
conﬁdence interval [CI]: 0.72 to 2.14; p ¼ 0.44), cardiac death or MI (HR: 1.12; 95% CI: 0.58 to 2.19;
p ¼ 0.73), or TLF (HR: 1.39; 95% CI: 0.99 to 1.94; p ¼ 0.06) in the non-LM bifurcation group. In contrast,
in patients with LM bifurcation lesions, the 2-stent strategy was associated with a higher incidence of
cardiac death (HR: 2.43; 95% CI: 1.05 to 5.59; p ¼ 0.04), cardiac death or MI (HR: 2.09; 95% CI: 1.08 to
4.04; p ¼ 0.03), as well as TLF (HR: 2.38; 95% CI: 1.60 to 3.55; p < 0.01). Signiﬁcant interactions were
present between treatment strategies and bifurcation lesion locations for TLF (p ¼ 0.01).
Conclusions The 1-stent strategy, if possible, should initially be considered the preferred approach for
the treatment of coronary bifurcation lesions, especially LM bifurcation lesions. (Korean Coronary
Bifurcation Stenting [COBIS] Registry II; NCT01642992) (J Am Coll Cardiol Intv 2014;7:255–63)
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256Coronary bifurcation lesions are 1 of the most challenging unless they had previously received these medications.
lesion subsets to treat and are known to have lower angio-
graphic success rates, a higher risk of procedural complica-
tions, and a greater restenosis rate than nonbifurcation lesions,
even in the drug-eluting stent (DES) era (1,2). A number of
studies comparing the 1- and 2-stent strategies for bifurcation
lesions have been performed (3–5), but there are limited data
comparing the efﬁcacy and safety of these strategies according
to the anatomic location of the bifurcation lesion. Therefore,
we sought to investigate whether the impact of treatmentSee page 264strategies on clinical outcomes differed between patients with
left main (LM) bifurcation lesions and those with non-LM
bifurcation lesions using data from a dedicated bifurcation
multicenter real-world registry.Korea; xxSamsung Changwon Hospit
cine, Changwon, Republic of Korea
Daegu, Republic of Korea. This wo
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Abbreviations
and Acronyms
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
LM = left main
MI = myocardial infarction
MLD = minimal lumen
diameter
MV = main vessel
PCI = percutaneous coronary
intervention
RD = reference diameter
SB = side branchMethods
Study population. The COBIS
(Coronary Bifurcation Stenting)
Registry II is a retrospective mul-
ticenter registry dedicated to
bifurcation lesions treated with
percutaneous coronary interven-
tion (PCI) with DES. From
January 2003 throughDecember
2009, 2,897 consecutive patients
were enrolled from 18 major cor-
onary intervention centers in the
Republic of Korea. The inclusion
criteria were coronary bifurcation
lesions treated solely with DES, a
main vessel (MV) diameter 2.5mm, and a side branch (SB) diameter 2.3 mm. The exclu-
sion criteria were cardiogenic shock, cardiopulmonary resus-
citation, and protected LM disease. This registry was funded
by the Korean Society of Interventional Cardiology. The local
institutional review board at each hospital approved this study
and waived the requirement for informed consent for access
to each institution’s PCI registry.
Percutaneous coronary intervention. All interventions were
performed according to current standard guidelines. All
patients received dual oral antiplatelet therapy with 300 mg
aspirin and either 300 or 600 mg clopidogrel before PCIal, Sungkyunkwan University School of Medi-
; and the kkYeungnam University Hospital,
rk was supported by the Korean Society of
rs have reported that they have no relationships
to disclose.
vised manuscript received November 12, 2013,Intravenous heparin was administered to maintain an acti-
vated clotting time of 250 to 300 s. The access, type of
DES, and use of intravascular ultrasound or glycoprotein
IIb/IIIa receptor inhibitors were all left to the operator’s
discretion. Decisions to treat bifurcation lesions by a 1- or
2-stent technique were made by the individual operators.
Aspirin was continued indeﬁnitely, and the duration
of clopidogrel treatment was also left to the operator’s
discretion.
Data collection and analysis. Clinical, angiographic, pro-
cedural, and outcome data were collected with the use of a
Web-based reporting system. Additional information was
obtained by further inquiry into medical records or tele-
phone contact, if necessary. All baseline and procedural
cine coronary angiograms were reviewed and quantitatively
analyzed at the angiographic core laboratory (the Cardiac
and Vascular Center, Samsung Medical Center, Seoul,
Republic of Korea) using standard qualitative and quan-
titative analyses and deﬁnitions (6). We determined the
minimal lumen diameter (MLD) and reference diameter
(RD) for each vessel. The percentage of diameter stenosis
was calculated as: 100  (RD  MLD)/RD. The bifur-
cation angle was deﬁned as the angle between the distal
MV and the SB at its origin using the angiographic
projection with the widest separation of the 2 branches
(7). Bifurcation lesions were classiﬁed according to the
Medina classiﬁcation, in which the proximal MV, distal
MV, and SB components of the bifurcation are each
assigned a score of 1 or 0 depending on the presence or
absence of >50% stenosis (8). Medina classiﬁcation type
1.1.1, 1.0.1, and 0.1.1 lesions were deﬁned as true bifur-
cation lesions.
Study outcomes and deﬁnitions. The primary endpoint of
the study was target lesion failure, deﬁned as a composite of
cardiac death, spontaneous myocardial infarction (MI), and
target lesion revascularization during follow-up. Secondary
endpoints were the individual components of the primary
endpoint, composite of cardiac death or spontaneous MI,
stent thrombosis, and target vessel revascularization.
All deaths were considered cardiac unless a deﬁnite
noncardiac cause could be established. MI was deﬁned as
elevated cardiac enzymes (troponin or creatine kinase-
myocardial band) greater than the upper limit of the normal
with ischemic symptoms or electrocardiographic ﬁndings
indicative of ischemia that was not related to the index
procedure. Target lesion revascularization was deﬁned as
repeat PCI of the lesion within 5 mm of stent deployment
or bypass graft surgery of the target vessel. Target vessel
revascularization was the repeat revascularization of the
target vessel by PCI or bypass graft surgery. Stent throm-
bosis was assessed based on the deﬁnitions of the Academic
Research Consortium (9). An independent clinical event
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257adjudicating committee reviewed all outcome data reported
from the participating centers.
Statistical analyses. Continuous variables are presented as
mean  SD or the median and interquartile range and were
compared using the t test or Wilcoxon rank sum test for
continuous variables. Categorical variables are reported as
frequencies (percentages) and were compared using the chi-
square or Fisher exact test, as appropriate. Survival curves
were constructed using Kaplan-Meier estimates and were
compared using the log-rank test.
To ensure a rigorous adjustment for signiﬁcant difference
in patient characteristics according to treatment strategy and
to avoid model overﬁtting based on few events in the
endpoints, we used a weighted Cox proportional hazards
model using inverse probability of treatment weighting (10).
A propensity score analysis was performed with a logistic
regression model from which the probability for the 2-stent
strategy was calculated for each patient. In the weighted
Cox multivariable model with inverse probability of treat-
ment weighting methods, the weights for patients under-
going the 2-stent strategy were the inverse of 1  propensity
score, and weights for patients not undergoing the 2-stent
strategy were the inverse of the propensity score. We also
tested the signiﬁcance of interactions between treatment
strategy and location of bifurcation lesion on outcomes in
these models.
All reported p values are 2-tailed, and p < 0.05 was
considered signiﬁcant. All analyses were performed using
SAS version 9.1 (SAS Institute, Cary, North Carolina).Table 1. Baseline Clinical Characteristics
Non-LM Bifurcation (n ¼
1-Stent
(n ¼ 1,618)
2-Stent
(n ¼ 426)
Age, yrs 61.8  10.3 61.3  10.7
65 yrs 637 (39.4) 170 (39.9)
Male 1,152 (71.2) 296 (69.5)
Acute coronary syndrome 1,078 (66.6) 279 (65.5)
Current smoker 437 (27.0) 100 (23.5)
Diabetes mellitus 445 (27.5) 122 (28.6)
Hypertension 936 (57.8) 242 (56.8)
Dyslipidemia 535 (33.1) 123 (28.9)
Family history of CAD 46 (2.8) 10 (2.3)
Peripheral vascular disease 18 (1.1) 2 (0.5)
Previous myocardial infarction 86 (5.3) 30 (7.0)
Previous cerebrovascular event 83 (5.1) 24 (5.6)
Previous PCI 170 (10.5) 67 (15.7)
Chronic kidney disease 40 (2.5) 10 (2.3)
LVEF, %* 57.3  11.1 58.9  12.0
<50% 283 (20.7) 62 (18.0)
Values are mean  SD or n (%). *LVEF was available in 688 LM bifurcation p
CAD ¼ coronary artery disease; LM ¼ left main; LVEF ¼ left ventricular ejeResults
Patient characteristics. Of the 2,897 patients registered in
the COBIS II registry, 2,044 patients (70.6%) had a non-
LM bifurcation lesion and 853 (29.4%) had an LM bifur-
cation lesion. The 2-stent strategy was used more frequently
in the LM bifurcation group than in the non-LM bifurca-
tion group (40.3% vs. 20.8%, p < 0.01).
Baseline demographic, clinical, angiographic, and proce-
dural characteristics according to bifurcation lesion locations
and treatment strategies are shown in Tables 1 and 2. In the
non-LM bifurcation group, patients undergoing the 2-stent
strategy had a higher prevalence of left anterior descending
artery bifurcation lesions and previous PCI than those un-
dergoing the 1-stent strategy. In the LM bifurcation group,
patients undergoing the 2-stent strategy were older and had
a higher prevalence of previous PCI and acute coronary
syndrome on admission than those undergoing the 1-stent
strategy. Compared with patients undergoing the 1-stent
strategy, those undergoing the 2-stent strategy were more
likely to have multivessel disease and true bifurcation lesions
on Medina classiﬁcation and more frequently underwent
ﬁnal kissing balloon dilation, intravascular ultrasound, and
remote-site intervention in both non-LM and LM bifur-
cation groups. The SYNTAX (Synergy between PCI with
Taxus and Cardiac Surgery) score was signiﬁcantly greater
in patients undergoing the 2-stent strategy than in those
undergoing the 1-stent strategy in both groups. Among the
2-stent group, the crush technique was used most frequently,2,044) LM Bifurcation (n ¼ 853)
p Value
1-Stent
(n ¼ 509)
2-Stent
(n ¼ 344) p Value
0.32 62.6  10.0 64.0  9.7 0.05
0.84 208 (40.9) 155 (45.1) 0.22
0.49 387 (76.0) 248 (72.1) 0.20
0.66 250 (49.1) 217 (63.1) <0.01
014 121 (23.8) 75 (21.8) 0.50
0.64 166 (32.6) 107 (31.1) 0.64
0.70 290 (57.0) 207 (60.2) 0.35
0.10 138 (27.1) 110 (32.0) 0.13
0.58 20 (3.9) 6 (1.7) 0.07
0.23 9 (1.8) 10 (2.9) 0.27
0.17 27 (5.3) 30 (8.7) 0.50
0.68 51 (10.0) 31 (9.0) 0.62
<0.01 91 (17.9) 86 (25.0) 0.01
0.88 19 (3.7) 12 (3.5) 0.85
0.03 59.6  11.5 59.0  11.8 0.50
0.26 59 (14.3) 50 (18.2) 0.17
atients and 1,079 non-LMB patients.
ction fraction; PCI ¼ percutaneous coronary intervention.
Table 2. Angiographic and Procedural Characteristics
Non-LM Bifurcation (n ¼ 2,044) LM Bifurcation (n ¼ 853)
1-Stent
(n ¼ 1,618)
2-Stent
(n ¼ 426) p Value
1-Stent
(n ¼ 509)
2-Stent
(n ¼ 344) p Value
Vessel involved <0.01
LAD/diagonal 1,191 (73.6) 360 (84.5)
LCX/OM 308 (19.0) 41 (9.6)
RCA bifurcation 119 (7.4) 25 (5.9)
Multivessel disease 729 (45.1) 200 (46.9) 0.49 230 (45.2) 283 (82.3) <0.01
SYNTAX score 14.9  7.6 16.7  7.6 <0.01 21.1  9.2 25.0  9.4 <0.01
Low score (0–22) 1,354 (83.7) 347 (81.5) 309 (60.7) 128 (37.2)
Intermediate score (23–32) 222 (13.7) 63 (14.8) 152 (29.9) 152 (44.2)
High score (33) 42 (2.6) 16 (3.8) 48 (9.4) 64 (18.6)
Medina classiﬁcation <0.01 <0.01
True bifurcation 814 (50.3) 330 (77.5) 114 (22.4) 244 (70.9)
1.1.1 502 (31.0) 189 (44.4) 79 (15.5) 168 (48.8)
1.0.1 130 (8.0) 30 (7.0) 23 (4.5) 28 (8.1)
0.1.1 182 (11.2) 111 (26.1) 12 (2.4) 48 (14.0)
Nontrue bifurcation 804 (49.7) 96 (22.5) 395 (77.6) 100 (29.1)
1.0.0 250 (15.5) 8 (1.9) 80 (15.7) 8 (2.3)
0.1.0 290 (17.9) 25 (5.9) 170 (33.4) 23 (6.7)
1.1.0 243 (15.0) 24 (5.6) 125 (24.6) 35 (10.2)
0.0.1 21 (1.3) 39 (9.2) 20 (3.9) 34 (9.9)
Stent type <0.01 0.01
SES 744 (46.0) 237 (55.6) 248 (48.7) 185 (53.8)
PES 509 (31.5) 120 (28.2) 105 (20.6) 88 (25.6)
EES 175 (10.8) 37 (8.7) 97 (19.1) 39 (11.3)
ZES 189 (11.7) 32 (7.5) 58 (11.4) 30 (8.7)
Others 1 (0.1) 0 1 (0.2) 2 (0.6)
Stenting technique
1-stent technique 1,618 (100.0) d 509 (100.0) d
2-stent techniques d 426 (100) d 344 (100.0)
T-stenting d 153 (35.9) d 124 (36.0)
Crush d 226 (53.1) d 143 (41.6)
Kissing or V stenting d 36 (8.5) d 60 (17.4)
Culottes d 9 (2.1) d 12 (3.5)
Others d 2 (0.5) d 5 (1.5)
Final kissing balloon inﬂation 502 (31.0) 348 (81.7) <0.01 191 (37.5) 308 (89.5) <0.01
Guidance of intravascular ultrasound 434 (26.8) 203 (47.7) <0.01 273 (53.6) 213 (61.9) 0.02
Remote site intervention 426 (26.3) 133 (31.2) 0.04 122 (24.0) 118 (34.3) <0.01
Main vessel
Total stent length, mm 28.9  11.9 30.0  11.3 0.09 27.4  13.4 28.6  13.8 0.20
Maximal stent diameter, mm 3.10  0.38 3.15  0.34 0.03 3.46  0.38 3.37  0.36 <0.01
Side branch
Total stent length, mm d 21.6  7.6 d d 22.6  11.0 d
Maximal stent diameter, mm d 2.74  0.25 d d 3.14  0.38 d
Values are n (%) or mean  SD.
EES ¼ everolimus-eluting stent(s); LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; LM ¼ left main; OM ¼ obtuse marginal branch;
PES ¼ paclitaxel-eluting stent(s); RCA ¼ right coronary artery; SES ¼ sirolimus-eluting stent(s); ZES ¼ zotarolimus-eluting stent(s).
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258followed by the T-stenting technique, kissing, or V-stenting
technique, and culottes stenting technique in both non-LM
and LM bifurcation groups.
Quantitative coronary angiographic analysis. In both LM
and non-LM bifurcation groups, patients who underwentthe 2-stent strategy had signiﬁcantly smaller RD and MLD
of the SB, a greater percentage of diameter stenosis of the
SB, and a longer lesion length of the MV and SB than those
in the 1-stent strategy group (Table 3). In the non-LM
bifurcation group, the angle between the MV and SB was
Table 3. Quantitative Coronary Angiographic Analysis
Non-LM Bifurcation (n ¼ 2,044) LM Bifurcation (n ¼ 853)
1-Stent
(n ¼ 1,618)
2-Stent
(n ¼ 426) p Value
1-Stent
(n ¼ 509)
2-Stent
(n ¼ 344) p Value
Bifurcation angle,  54.0 (43.0 to 68.0) 50.0 (40.0 to 62.0) <0.01 81.2 (62.9 to 102.2) 78.2 (64.1 to 99.8) 0.30
Pre-intervention
MV RD, mm 2.9 (2.7 to 3.2) 2.9 (2.6 to 3.1) 0.04 3.4 (3.0 to 3.7) 3.3 (3.0 to 3.6) 0.01
SB RD, mm 2.4 (2.3 to 2.5) 2.4 (2.2 to 2.5) <0.01 2.8 (2.5 to 3.3) 2.7 (2.4 to 3.0) <0.01
MV MLD, mm 0.9 (0.6 to 1.2) 0.9 (0.6 to 1.3) <0.01 1.2 (0.8 to 1.6) 1.2 (0.9 to 1.5) 0.43
SB MLD, mm 1.3 (0.9 to 1.8) 0.9 (0.5 to 1.2) <0.01 2.2 (1.6 to 2.6) 1.2 (0.9 to 1.6) <0.01
MV diameter stenosis, % 70.1  14.4 67.1  17.0 <0.01 63.6  17.7 63.6  16.0 0.98
SB diameter stenosis, % 44.7  22.5 62.8  19.2 <0.01 28.9  22.3 53.1  19.1 <0.01
MV lesion length, mm 16.4 (10.5 to 24.3) 18.8 (11.0 to 28.5) 0.01 12.3 (7.8 to 22.6) 14.8 (9.2 to 24.5) <0.01
SB lesion length, mm 1.1 (0 to 6.0) 9.3 (4.6 to 16.1) <0.01 0 (0 to 2.3) 6.9 (3.5 to 14.1) <0.01
Post-intervention
MV RD, mm 3.0 (2.7 to 3.2) 2.9 (2.7 to 3.2) <0.01 3.4 (3.0 to 3.8) 3.4 (3.0 to 3.7) 0.38
SB RD, mm 2.4 (2.3 to 2.5) 2.4 (2.3 to 2.5) 0.04 2.8 (2.5 to 3.3) 2.8 (2.4 to 3.2) 0.01
MV MLD, mm 2.6 (2.3 to 2.9) 2.6 (2.3 to 2.9) 0.95 2.9 (2.6 to 3.3) 2.8 (2.5 to 3.1) <0.01
SB MLD, mm 1.34 (1.0 to 1.8) 2.2 (1.9 to 2.4) <0.01 2.2 (1.8 to 2.6) 2.5 (2.3 to 3.0) <0.01
MV residual stenosis, % 14.1  13.2 12.3  11.4 <0.01 14.0  12.9 16.5  11.1 <0.01
SB residual stenosis, % 44.3  22.3 8.9  15.9 <0.01 25.0  18.8 6.8  15.0 <0.01
MV acute gain, mm 1.68 (1.3 to 2.0) 1.6 (1.2 to 2.0) 0.02 1.8 (1.3 to 2.2) 1.6 (1.3 to 2.0) 0.11
SB acute gain, mm 0 (0.3 to 0.3) 1.3 (1.0 to 1.6) <0.01 0 (0.3 to 0.3) 1.4 (1.0 to 1.7) <0.01
Values are median (interquartile range) or mean  SD.
LM ¼ left main; MLD ¼ minimal lumen diameter; MV ¼ main vessel; RD ¼ reference diameter; SB ¼ side branch.
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259signiﬁcantly smaller in patients in whom the 2-stent strategy
was used than in those who underwent the 1-stent strategy,
but in the LM bifurcation group, the angle between the MV
and SB was similar.
Clinical outcomes according to bifurcation lesion locations
and treatment strategies. Complete clinical follow-up data
for major clinical events were obtained in 96.0% and 97.4%
of patients who underwent the 1- and 2-stent strategies for
non-LM bifurcation lesions (p ¼ 0.18), and 96.3% and
96.5% for LM bifurcation lesions (p ¼ 0.85), respectively.
The median follow-up was 37 months (interquartile range:Table 4. Clinical Outcome Rates According to Treatment Strategy in Patients W
Non-LM Bifurcation (n ¼ 2,04
1-Stent
(n ¼ 1,618)
2-Stent
(n ¼ 426) HR (95%
Target lesion failure 130 (8.0) 52 (12.2) 1.51 (1.10–2
Cardiac death 16 (1.0) 4 (0.9) 0.91 (0.30–2
Spontaneous myocardial infarction 22 (1.4) 11 (2.6) 1.77 (0.86–3
Cardiac death or myocardial infarction 36 (2.2) 14 (3.3) 1.40 (0.75–2
Deﬁnite or probable stent thrombosis 8 (0.5) 5 (1.2) 2.26 (0.74–6
Target lesion revascularization 104 (6.4) 43 (10.1) 1.56 (1.09–2
Target vessel revascularization 150 (9.3) 53 (12.4) 1.32 (0.97–1
Values are n (%) unless otherwise indicated.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LM ¼ left main.25 to 53 months) in the non-LM bifurcation group and
35 months (interquartile range: 25 to 50 months) in the LM
bifurcation group.
During the entire study period, 182 primary composite
events occurred, including 20 cardiac deaths, 33 spontaneous
MIs, and 147 target lesion revascularizations in the non-LM
bifurcation group. In the LM bifurcation group, 114 pri-
mary composite events occurred, including 22 cardiac
deaths, 20 spontaneous MIs, and 83 target lesion re-
vascularizations. Observed clinical outcomes according to
bifurcation lesion location and treatment strategy are shownith LM Bifurcation Lesions and Non-LM Bifurcation Lesions
4) LM Bifurcation (n ¼ 853)
CI) p Value
1-Stent
(n ¼ 509)
2-Stent
(n ¼ 344) HR (95% CI) p Value
.09) 0.01 41 (8.1) 73 (21.2) 2.77 (1.89–4.06) <0.01
.72) 0.86 8 (1.6) 14 (4.1) 2.51 (1.05–5.98) 0.03
.65) 0.12 8 (1.6) 12 (3.5) 2.22 (0.91–5.43) 0.08
.59) 0.29 16 (3.1) 24 (7.0) 2.21 (1.17–4.16) 0.01
.91) 0.15 3 (0.6) 11 (3.2) 5.35 (1.49–19.2) 0.01
.23) 0.01 29 (5.7) 54 (15.7) 2.89 (1.84–4.54) <0.01
.81) 0.08 50 (9.8) 77 (22.4) 2.45 (1.72–3.50) <0.01
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260in Table 4. In the non-LM bifurcation group, treatment
with the 2-stent strategy was associated with a higher inci-
dence of target lesion failure and target lesion revasculari-
zation, but not cardiac death and the composite of cardiac
death or MI (Fig. 1).
In contrast, among patients with the LM bifurcation le-
sions, patients who underwent the 2-stent strategy had a
higher incidence of cardiac death, the composite of cardiac
death or MI, target lesion revascularization, and target lesion
failure (Fig. 2). In addition, deﬁnite or probable stent
thrombosis occurred more frequently in the 2-stent group
than in the 1-stent group.
After adjustments of clinical covariates using an inverse
probability of treatment weighting method (Table 5), the
adjusted risks for primary (hazard ratio [HR]: 1.39; 95%
conﬁdence interval [CI]: 0.99 to 1.94; p ¼ 0.06) and any
secondary endpoints were not signiﬁcantly different ac-
cording to treatment strategy except for target lesion revas-
cularization in patients with non-LM bifurcation lesions.Figure 1. Kaplan-Meier Curves in Patients With Non-LM Bifurcation Lesions
(A) Kaplan-Meier curves for target lesion failure in patients undergoing the 1-stent s
patients undergoing the 1-stent strategy versus the 2-stent strategy. (C) Kaplan-Mei
1-stent strategy versus the 2-stent strategy. (D) Kaplan-Meier curves for target lesion
strategy. LM ¼ left main.On the other hand, in the LM bifurcation group, the
adjusted risks for the primary endpoint (HR: 2.38; 95% CI:
1.60 to 3.55; p < 0.01) and all secondary endpoints were
signiﬁcantly higher in patients treated with the 2-stent
strategy than in those treated with the 1-stent strategy.
There were statistically signiﬁcant interactions between
treatment strategies and bifurcation lesion locations for co-
variate-adjusted risks of target lesion failure (p ¼ 0.01),
target lesion revascularization (p ¼ 0.03), and target vessel
revascularization (p < 0.01). There was also a nonsigniﬁcant
trend in the interaction between treatment strategy and
bifurcation lesion location for the composite of cardiac death
or MI (p ¼ 0.06).
Discussion
In the present study, we compared the prognostic impact of
treatment strategy on clinical outcomes according to bifur-
cation lesion location (LM vs. non-LM bifurcation lesion)trategy versus the 2-stent strategy. (B) Kaplan-Meier curves for cardiac death in
er curves for cardiac death or myocardial infarction in patients undergoing the
revascularization in patients undergoing the 1-stent strategy versus the 2-stent
Figure 2. Kaplan-Meier Curves in Patients With LM Bifurcation Lesions
Kaplan-Meier curves for (A) target lesion failure, (B) cardiac death, (C) cardiac death or myocardial infarction, and (D) target lesion revascularization in patients
undergoing the 1-stent strategy versus the 2-stent strategy. LM ¼ left main.
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261using data from a large, multicenter, dedicated bifurcation
registry. The main ﬁndings of the present study are that
compared with the 1-stent strategy, the 2-stent strategy was
associated with higher risks of cardiovascular events in pa-
tients with LM bifurcation lesion, whereas this associationTable 5. Adjusted Hazard Ratios for the 2-Stent Technique
Probability of Treatment Weighting Method
Non-LM Bifurcation
(n ¼ 2,044)
HR (95% CI) p V
Target lesion failure 1.39 (0.99–1.94) 0
Cardiac death 1.24 (0.72–2.14) 0
Spontaneous myocardial infarction 1.40 (0.64–3.09) 0
Cardiac death or myocardial infarction 1.12 (0.58–2.19) 0
Deﬁnite or probable stent thrombosis 1.95 (0.64–5.98) 0
Target lesion revascularization 1.48 (1.02–2.13) 0
Target vessel revascularization 1.26 (0.92–1.74) 0
Abbreviations as in Table 4.was attenuated in those with non-LM bifurcation lesions,
and that signiﬁcant interactions were present between
treatment strategy and bifurcation lesion location in the
adjusted risks of target lesion failure, target lesion revascu-
larization, and target vessel revascularization.for the Clinical Outcomes Using Inverse
LM Bifurcation
(n ¼ 853)
Interaction p Valuealue HR (95% CI) p Value
.06 2.38 (1.60–3.55) <0.01 <0.01
.44 2.43 (1.05–5.59) 0.04 0.12
.40 3.32 (1.23–8.98) 0.02 0.25
.73 2.09 (1.08–4.04) 0.03 0.06
.24 4.58 (1.43–14.7) 0.01 0.12
.04 2.44 (1.50–3.96) <0.01 0.04
.15 2.12 (1.45–3.08) <0.01 <0.01
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262Coronary bifurcation lesions are complex, and their
treatment continues to be the subject of substantial debate,
even in the DES era (1,2). Previous randomized trials
comparing the 1-stent strategy with the elective 2-stent
strategy (mainly in patients with non-LM bifurcation le-
sions) consistently found no signiﬁcant differences in the
major adverse cardiovascular event rate (3–5). In contrast,
several observational studies including only patients with LM
bifurcation lesions have shown that, compared with the
1-stent strategy, the 2-stent strategy was associated with
higher rates of cardiac death, MI, or target lesion revascu-
larization (11,12). Even though this discrepancy between
previous studies may be attributable to a selection bias in the
observational studies as a result of more complex lesions in
the 2-stent group, there are limited data regarding whether
the impact of treatment strategy on clinical outcomes would
differ between patients with LM bifurcation lesions and
those with non-LM bifurcation lesions. In addition,
considering that LM bifurcation lesions are increasingly
treated with PCI in real-world practice, it is very important
to investigate whether treatment strategies are of similar
prognostic value for different bifurcation lesion locations.
One previous study addressed this issue, but has several
limitations; the registry studied was not dedicated to treat-
ment of bifurcation lesions, follow-up was relatively short,
and the authors only compared the LM and left anterior
descending artery strata (13). Therefore, we examined the
long-term comparative efﬁcacy and safety of the 1- versus 2-
stent treatment strategies according to different bifurcation
lesion locations using data from the COBIS II registry. The
COBIS II registry is a large, nationwide multicenter registry
dedicated solely to coronary bifurcation lesions treated only
with DES.
The present study found that the 2-stent strategy had a
strong association with adverse cardiovascular events
including cardiac death or MI, stent thrombosis, and target
lesion revascularization in patients with LM bifurcation le-
sions. These ﬁndings are in line with ﬁndings from previous
studies that compared different strategies of revasculariza-
tion for LM bifurcation lesions (11,12,14). On the other
hand, for the treatment of non-LM bifurcation lesions, this
association was attenuated, with no signiﬁcant difference in
cardiac mortality, MI risk, and target lesion failure, although
there was still a higher risk of target lesion revascularization
in patients treated with the 2-stent strategy. Moreover,
signiﬁcant interactions were observed between treatment
strategy and bifurcation lesion location in the adjusted risks
of target lesion failure, target lesion revascularization, and
target vessel revascularization.
There are several possible explanations for the differ-
ences in clinical outcomes according to stenting strategy
between LM and non-LM bifurcation lesions. First, a
high bifurcation angle has been known to be an inde-
pendent predictor of increased major adverse cardiacevents, especially in the crush or culottes stenting tech-
nique, whereas no such association was observed in the 1-
stent group (15). In the present study, the LM bifurcation
group had a higher bifurcation angle compared with the
non-LM bifurcation group, and the crush technique was
used most frequently in both groups. Second, it is well-
known that proper stent expansion is crucial to prevent
restenosis and thrombosis (16,17). Several bench studies
have shown that a higher bifurcation angle is associated
with less expansion and apposition of the SB stent (18,19).
In addition, a previous intravascular ultrasound imaging
study evaluating 403 patients treated with PCI for LM
bifurcation lesions found that the frequency of stent
underexpansion in the 2-stent group was twice as high as
that in the 1-stent group, which could explain the higher
risk of adverse cardiovascular events in patients treated
with the 2-stent strategy (20).
The main point of the present study is that, if possible,
the 1-stent strategy should initially be considered as the
preferred approach for the treatment of coronary bifurcation
lesions, especially in patients with LM bifurcation lesions. In
the present study, w60% of patients with LM bifurcation
lesions were treated with the 1-stent strategy, which is
consistent with previous reports (11,12). We previously re-
ported that the 1-stent strategy with provisional SB stenting
for LM bifurcation lesions was feasible and effective and that
the crossover rate to the 2-stent technique was only 12.5%
when SB stenting was performed only if there was diameter
stenosis >50% or type B or greater dissection after main
vessel stenting followed by kissing balloon dilation (21).
Therefore, the 1-stent strategy may be performed in the
majority of patients with LM bifurcation lesions and is
associated with favorable clinical outcomes. However,
considering the higher risk of stent thrombosis, cardiac
death, and MI as well as repeat revascularization observed in
patients treated with the 2-stent technique compared with
those treated with the 1-stent technique, a careful surgical
evaluation should take place in patients with LM bifurcation
lesions requiring an elective 2-stent technique.
Study limitations. Our study ’s nonrandomized, observa-
tional design may have signiﬁcantly affected the results due
to confounding factors. The selection of treatment strategy
and stent type was at the discretion of the operators. Some
baseline and angiographic characteristics were unfavorable to
the 2-stent group compared with the 1-stent group. This
may contribute to differences in adverse outcomes between
the 2 groups, and the impact of the 2-stent strategy on
adverse clinical outcomes could become more relevant in
patients with LM bifurcation lesions. Although we strove to
reduce treatment-selection bias for treatment strategy
and potential confounding using various risk-adjusted and
inverse probability of treatment weighting, unmeasured
confounders may be present. Another limitation is that
a substantial portion of patients were treated with ﬁrst-
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263generation DES, which were found to be inferior to newer
generation DES with regard to the occurrence of adverse
clinical events. Our ﬁndings should be conﬁrmed by
adequately powered, randomized trials using newer genera-
tion DES.
Conclusions
There was a substantial interaction between treatment
strategy and bifurcation lesion location for cardiovascular
events. The 1-stent strategy, if anatomically suitable, should
be considered the primary strategy for the treatment of
coronary bifurcation lesions, especially LM bifurcation
lesions. Randomized, controlled trials with a large sample
size are needed to conﬁrm these ﬁndings.
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